Acuta Capital Partners LLC Has $360,000 Holdings in Rapport Therapeutics (NASDAQ:RAPP)

Acuta Capital Partners LLC decreased its holdings in shares of Rapport Therapeutics (NASDAQ:RAPP) by 12.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,600 shares of the company’s stock after selling 2,400 shares during the quarter. Acuta Capital Partners LLC’s holdings in Rapport Therapeutics were worth $360,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. TD Asset Management Inc acquired a new stake in Rapport Therapeutics during the 2nd quarter worth $2,361,000. Johnson & Johnson acquired a new stake in shares of Rapport Therapeutics during the second quarter worth $58,105,000. Sofinnova Investments Inc. bought a new stake in Rapport Therapeutics in the second quarter valued at about $45,393,000. Davidson Kempner Capital Management LP acquired a new position in Rapport Therapeutics in the second quarter valued at about $229,000. Finally, ARCH Venture Management LLC bought a new position in Rapport Therapeutics during the second quarter worth about $86,730,000.

Rapport Therapeutics Price Performance

Shares of RAPP stock opened at $22.39 on Thursday. The company has a 50-day moving average of $23.04. Rapport Therapeutics has a one year low of $16.55 and a one year high of $29.74.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.